HealthBeacon SHA

Report Publication Announcement • May 6, 2022

National Storage Mechanism | Additional information

RNS Number : 5245K

HealthBeacon PLC

06 May 2022

6 May 2022

HealthBeacon plc

Annual Report and Notice of Annual General Meeting

Dublin, HealthBeacon plc ("HealthBeacon" or "the Company"), today announces that its Annual Report for the year ended 31 December 2021, together with the Letter from the Chairman, Notice of Annual General Meeting and Form of Proxy have been issued to shareholders.

The Annual General Meeting will be held on 2 June 2022 at 10am in The Herbert Park Hotel, Ballsbridge, Dublin 4, D04 R2T2.

Copies of the Annual Report, Chairman's Letter, Notice AGM and Form of Proxy are available online at https://healthbeacon.com/agm.

For further information, contact:

HealthBeacon plc

Unit 20

Naas Road Business Park

Muirfield Drive

Naas Road

Dublin 12

D12 WD85

T: +353 1 4508480

E: company.secretary@healthbeacon.com

Goodbody Stockbrokers (Euronext Listing Sponsor and Broker)

David Kearney

Stephen Kane

T: +353 (1) 667 0420

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. The Company operates in 17 countries primarily across Europe, North America and the United Kingdom employs more than 70 people and has obtained more than 30 design and utility patents. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and a 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company's mission is to become the world's leading digital therapeutics platform for injectable medications. 

Ends

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEBLGDUXBGDGDU